US8383340B2 - Method for purifying RNA on a preparative scale by means of HPLC - Google Patents

Method for purifying RNA on a preparative scale by means of HPLC Download PDF

Info

Publication number
US8383340B2
US8383340B2 US12/520,172 US52017207A US8383340B2 US 8383340 B2 US8383340 B2 US 8383340B2 US 52017207 A US52017207 A US 52017207A US 8383340 B2 US8383340 B2 US 8383340B2
Authority
US
United States
Prior art keywords
rna
separation
hplc
organic solvent
mobile phase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US12/520,172
Other languages
English (en)
Other versions
US20100048883A1 (en
Inventor
Thomas Ketterer
Florian Von Der Mulbe
Ladislaus Reidel
Thorsten Mutzke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Curevac Manufacturing GmbH
Original Assignee
Curevac AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39186980&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US8383340(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
PTAB case IPR2017-02194 filed (Final Written Decision) litigation https://portal.unifiedpatents.com/ptab/case/IPR2017-02194 Petitioner: "Unified Patents PTAB Data" by Unified Patents is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Curevac AG filed Critical Curevac AG
Assigned to CUREVAC GMBH reassignment CUREVAC GMBH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: VON DER MULBE, FLORIAN, MUTZKE, THORSTEN, REIDEL, LADISLAUS, KETTERER, THOMAS
Publication of US20100048883A1 publication Critical patent/US20100048883A1/en
Application granted granted Critical
Publication of US8383340B2 publication Critical patent/US8383340B2/en
Assigned to CUREVAC AG reassignment CUREVAC AG CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: CUREVAC GMBH
Assigned to CUREVAC REAL ESTATE GMBH reassignment CUREVAC REAL ESTATE GMBH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CUREVAC AG
Assigned to CureVac Manufacturing GmbH reassignment CureVac Manufacturing GmbH CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: CUREVAC REAL ESTATE GMBH
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
    • C12N15/101—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by chromatography, e.g. electrophoresis, ion-exchange, reverse phase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Definitions

  • the present invention relates to a method for purifying RNA on a preparative scale by means of HPLC and to the use of a porous reversed phase as stationary phase in this method.
  • HPLC abbreviation for “High Performance (High Pressure) Liquid Chromatography” is an established method of separating mixtures of substances, which is widely used in biochemistry, analytical chemistry and clinical chemistry.
  • RNA analysis using ion pair reversed phase HPLC is known from A. Azarani and K. H. Hecker (Nucleic Acids Research, vol. 29, no. 2 e7).
  • the stationary phase here consists of a non-porous alkylated polystyrenedivinylbenzene matrix. Elution proceeds with a buffer system of two eluents.
  • Buffer A consists of an aqueous solution of 0.1 M triethylammonium acetate (TEAA), pH 7.0
  • buffer B consists of an aqueous solution of 0.1 M TEAA, pH 7.0, with 25% acetonitrile.
  • the object of the present invention is here to improve a method of this type to the effect that it no longer exhibits the disadvantages of the prior art.
  • RNA is purified by means of HPLC using a porous reversed phase as stationary phase.
  • a porous reversed phase is used.
  • RMe 2 SiCl where R is a straight chain alkyl group such as C 18 H 37 or C 8 H 17 .
  • the retention time is therefore longer for molecules which are more non-polar in nature, allowing polar molecules to elute more readily. Retention time is increased by the addition of polar solvent to the mobile phase and decreased by the addition of more hydrophobic solvent.
  • RNA molecule as an analyte may play an important role in its retention characteristics.
  • an analyte having more apolar functional groups results in a longer retention time because it increases the molecule's hydrophobicity.
  • Very large molecules can result in incomplete interaction between the large analyte surface and the alkyl chain. Retention time increases with hydrophobic surface area which is roughly inversely proportional to solute size. Branched chain compounds elute more rapidly than their corresponding isomers because the overall surface area is decreased.
  • RNA molecule retention Aside from mobile phase hydrophobicity, other mobile phase modifiers can—according to the invention—affect analyte (RNA molecule) retention.
  • RNA molecule RNA molecule
  • the addition of inorganic salts may be considered to cause a linear increase in the surface tension of aqueous solutions, and because the entropy of the analyte-solvent interface is controlled by surface tension, the addition of salts tend to increase the retention time.
  • Another important component, which may be used according to the invention is pH, since this can change the hydrophobicity of the analyte. For this reason, a buffering agent, such as sodium phosphate or other common buffering agents, may be used to control the pH.
  • An organic acid such as formic acid or most commonly trifluoroacetic acid, may be added to mobile phase.
  • the above modifications may serve multiple purposes: They control pH, neutralize the charge on any residual exposed material on the stationary phase and act as ion pairing agents to neutralize charge on the analyte. The effect varies depending on use but generally improve the chromatography.
  • the term “purification” is understood to mean that the desired RNA in a sample is separated and/or isolated from the impurities present therein.
  • the RNA is present in a purer form than in the originally introduced RNA-containing sample prior to HPLC purification.
  • Undesired constituents of RNA-containing samples which therefore need to be separated may in particular be degraded fragments or fragments which have arisen as a result of premature termination of transcription, or also excessively long transcripts if plasmids are not completely linearised.
  • impurities such as enzymes, for example RNases and polymerases, and nucleotides may be separated.
  • RNA is purified which has a higher purity after purification than the starting material. It is desirable in this respect for the degree of purity to be as close as possible to 100%. A degree of purity of more than 70%, in particular 80%, very particularly 90% and most favourably 99% or more may be achieved in this way.
  • the method according to the invention results in preparative RNA purification.
  • an analytical HPLC method a distinctly smaller quantity is introduced and separated than in a preparative HPLC method.
  • quantities of 8 ng to 1000 ng were introduced.
  • a preparative HPLC method should be understood to mean an HPLC method in which relatively large quantities of RNA are purified.
  • Such relatively large quantities are for example quantities of 0.5 mg or more, in particular 1.0 mg to 1000 mg or more, very particularly approximately 1.5 mg or more, upscaling even to the kg range being possible.
  • the above statements are therefore to be understood to mean that these quantities relate to a single HPLC run. If a plurality of HPLC runs are performed, the quantity increases in direct proportion to the number of HPLC runs.
  • RNA is stable under the conditions of the method according to the invention, i.e. degradation during HPLC purification into RNA fragments and thus the occurrence of new impurities and a reduction in the yield of desired RNA during HPLC purification is avoided.
  • the method according to the invention may thus be performed in a simple, rapid, inexpensive manner, accurately and with reliable results. Isolation of RNA after HPLC separation may proceed simply with a fraction collector, i.e. the recovery of RNA may be achieved very simply, it being possible for direct further processing of the RNA likewise to take place. Detection may finally be performed very sensitively.
  • the “RNA” which is to be purified with the method according to the invention is ribonucleic acid of any type.
  • the RNA is particularly preferably selected from tRNA, rRNA, mRNA or whole-cell RNA.
  • the RNA may also comprise aptamers and ribozymes.
  • the RNA to be isolated may be single-stranded or double-stranded. Single-stranded RNA may optionally form secondary structures by refolding, the RNA to be separated typically being single-stranded.
  • the RNA may be unlabelled or also labelled (with a fluorescent label or a radiolabel or an antibody epitope).
  • a labelled RNA is digoxigenin-labelled ⁇ -actin RNA.
  • the RNA may also contain non-native nucleotides, wherein the chemical modifications may be present in the backbone of the RNA, for example phosphorthioate, in the structure of the nucleotide base, for example hypoxanthine, dihydrouracil, pseudouracil, 2-thiouracil, 4-thiouracil, 5-aminouracil, 5-(C1-C6)-alkyluracil, 5-(C2-C6)-alkenyluracil, 5-(C2-C6)-alkynyluracil, 5-(hydroxymethyl)uracil, 5-chlorouracil, 5-fluorouracil, 5-bromouracil, 5-hydroxycytosine, 5-(C1-C6)-alkylcytosine, 5-(C2-C6)-alkenylcytosine, 5-(C2-C6)-alkynylcytosine, 5-chlorocytosine, 5-fluorocytosine, 5-bromocytosine, N ⁇ 2>-di
  • modified nucleotides are 2-amino-6-chloropurine-riboside-5′-triphosphate, 2-aminoadenosine-5′-triphosphate, 2-thiocytidine-5′-triphosphate, 2-thiouridine-5′-triphosphate, 4-thiouridine-5′-triphosphate, 5-aminoallylcytidine-5′-triphosphate, 5-aminoallyluridine-5′-triphosphate, 5-bromocytidine-5′-triphosphate, 5-bromouridine-5′-triphosphate, 5-iodocytidine-5′-triphosphate, 5-iodouridine-5′-tri phosphate, 5-methylcytidine-5′-triphosphate, 5-methyluridine-5′-triphosphate, 6-azacytidine-5′-triphosphate, 6-azauridine-5′-triphosphate, 6-chloropurine-riboside-5′-triphosphate, 7-deazaadenosine-5′-triphosphate, 7-d
  • RNA to be separated is mRNA
  • this will preferably code for proteins, in particular those which have an antigen character, and for example all recombinantly produced or naturally occurring proteins, which are known to a person skilled in the art from the prior art and are used for therapeutic, diagnostic or research purposes.
  • the antigens are then tumour antigens or antigens of pathogens, for example viral, bacterial or protozoal organisms.
  • Such proteins further include enzymes, such as for example—galactosidase (lacZ), DNA restriction enzymes (for example EcoRI, HindIII, etc.), lysozymes, etc., or proteases, such as for example papain, bromelain, keratinases, trypsin, chymotrypsin, pepsin, rennin (chymosin), suizyme, nortase, etc., and protease inhibitors (for example for the treatment of HIV infections), such as for example protease inhibitors selected from a group consisting of AG1776, amprenavir (141W94 or VX-478), atazanavir (BMS-232632), cathepsin S protease inhibitor, D1927, D9120, fosamprenavir (GW-433908 or VX-175), GS 9005, GW640385 (VX-385), HCV protease inhibitor, indinavir (MK-639), L
  • the proteins coded from the RNA separated according to the invention may likewise comprise proteins which stimulate or inhibit cell signal transmission, for example cytokines, etc.
  • Such proteins therefore also comprise for example cytokines of class I of the cytokine family, which comprise 4 positionally conserved cysteine residues (CCCC) and one conserved sequence motif Trp-Ser-X-Trp-Ser (WSXWS), wherein X represents a non-conserved amino acid.
  • Cytokines of class I of the cytokine family comprise the GM-CSF subfamily, for example IL-3, IL-5, GM-CSF, the IL-6 subfamily, for example IL-6, IL-11, IL-12, or the IL-2 subfamily, for example IL-2, IL-4, IL-7, IL-9, IL-15, etc., or the cytokines IL-1, IL-1, IL-10 etc.
  • such proteins may also comprise cytokines of the class II of the cytokine family (interferon receptor family), which likewise comprise 4 positionally conserved cysteine residues (CCCC), but no conserved sequence motif Trp-Ser-X-Trp-Ser (WSXWS).
  • Cytokines of class II of the cytokine family include for example IFN-alpha, IFN-beta, IFN-gamma, etc.
  • the proteins coded by the separated RNA may furthermore also include cytokines of the tumour necrosis family including for example TNF-alpha, TNF-beta, CD40 ligand, Fas ligand, etc., or cytokines of the chemokine family, in particular interferons, interleukins, colony-stimulating factors and tumour necrosis factors, and interact with G protein, for example IL-8, MIP-1, RANTES, CCR5, CXR4, etc.
  • Such proteins may also be selected from apoptosis factors or apoptosis-related or -linked proteins, including AIF, Apaf, for example Apaf-1, Apaf-2, Apaf-3, or APO-2 (L), APO-3 (L), apopain, Bad, Bak, Bax, Bcl-2, Bcl-x L , Bcl-x S , bik, CAD, calpain, caspases for example caspase-1, caspase-2, caspase-3, caspase-4, caspase-5, caspase-6, caspase-7, caspase-8, caspase-9, caspase-10, caspase-11, ced-3, ced-9, c-Jun, c-Myc, crm A, cytochrome C, CdR1, DcR1, DD, DED, DISC, DNA-PK CS , DR3, DR4, DR5, FADD/MORT-1, FAK, Fas (Fas
  • the proteins coded by RNA separated according to the invention may also be selected from antigens, for example from tumour-specific surface antigens (TSSA), for example 5T4alpha5 beta1 integrin, 707-AP, AFP, ART-4, B7H4, BAGE, Bcr-abl, MN/C IX-antigen, CA125, CAMEL, CAP-1, CASP-8, beta-catenin/m, CD4, CD19, CD20, CD22, CD25, CDC27/m, CD30, CD33, CD52, CD56, CD80, CDK4/m, CEA, CT, Cyp-B, DAM, EGFR, ErbB3, ELF2M, EMMPRIN, EpCam, ETV6-AML1, G250, GAGE, GnT-V, Gp100, HAGE, HER-2/new, HLA-A*0201-R170I, HPV-E7, HSP70-2M, HAST-2, hTERT (or hTRT
  • Proteins which may be coded by the RNA separated according to the invention additionally also include proteins or protein sequences which exhibit sequence identity of at least 80% or 85%, preferably at least 90%, more preferably at least 95% and most preferably at least 99% to one of the above-described proteins.
  • the G/C content of the region of the modified mRNA coding for a peptide or polypeptide may be greater than the G/C content of the coding region of the wild-type mRNA coding for the peptide or polypeptide, the coded amino acid sequence being unchanged relative to the wild-type.
  • This modification is based on the fact that the sequence order of the mRNA domain to be translated is essential for efficient mRNA translation.
  • the composition and sequence of the various nucleotides has an important part to play. In particular, sequences with an elevated G(guanosine)/C(cytosine) content are more stable than sequences with an elevated A(adenosine)/U(uracil) content.
  • the codons are varied relative to the wild-type mRNA in such a manner that they have a greater content of G/C nucleotides. Since several codons code for one and the same amino acid (degeneration of the genetic code), it is possible to determine the codons which are most favourable for stability (alternative codon usage). On the other hand it is also possible to provide a translation-optimised RNA with the method according to the invention.
  • a reversed phase is used as the stationary phase for HPLC purification.
  • a nonpolar compound serves as the stationary phases and a polar solvent, such as mixtures of water, which is generally used in the form of buffers, with e.g. acetonitrile and/or methanol, serves as the mobile phase for elution.
  • the material packed on the column which is used as stationary phase, may be provided in bead form or as a polymerized “block”, i.e. a block which fills a substantial part of the chromatography column.
  • the polymeric stationary phase is porous in its nature, which means that the beads or the block are characterized by pores.
  • the reversed phase has a pore size of 1000 ⁇ to 5000 ⁇ , in particular a pore size of 1000 ⁇ to 4000 ⁇ , more preferably 1500 ⁇ to 4000 ⁇ , 2000 ⁇ to 4000 ⁇ or 2500 ⁇ to 4000 ⁇ .
  • Particularly preferred pore sizes for the reversed phases are 1000 ⁇ to 2000 ⁇ , more preferably 1000 ⁇ to 1500 ⁇ and most preferably 1000 ⁇ to 1200 ⁇ or 3500-4500 ⁇ .
  • a pore size of 1000 ⁇ to 5000 ⁇ , in particular a pore size of 1000 ⁇ to 4000 ⁇ , more preferably 1500 ⁇ to 4000 ⁇ , 2000 ⁇ to 4000 ⁇ or 2500 ⁇ to 4000 ⁇ may be suitable to separate a RNA from other components of a mixture, the RNA having a size as mentioned above of up to about 15000 nucleotides (as single stranded RNA molecule) or base pairs (as double stranded RNA molecule), in particular 100 to 10000, more preferably 500 to 10000 nucleotides or base pairs, even more preferably 800 to 5000 nucleotides or base pairs and even more preferably 800 to 2000 nucleotides or base pairs.
  • the pore size of the reversed phase may also be selected in dependence of the size of the RNA to be separated, i.e. a larger pore size may be selected, if larger RNA molecules are to be separated and smaller pore sizes may be selected, if smaller RNA molecules may be selected.
  • a larger pore size may be selected, if larger RNA molecules are to be separated and smaller pore sizes may be selected, if smaller RNA molecules may be selected.
  • a pore size for the reversed phase of about 2000 ⁇ to about 5000 ⁇ , more preferably of about 2500 to about 4000, most preferably of about 3500 to about 4500 ⁇ , may thus be used to separate larger RNA molecules, e.g. RNA molecules of 100 to 10000, more preferably 500 to 10000 nucleotides or base pairs, even more preferably 800 to 5000 nucleotides or base pairs and even more preferably 800 to 2000 nucleotides or base pairs.
  • a pore size of for the reversed phases of about 1000 ⁇ to about 2500 ⁇ , more preferably of about 1000 ⁇ to about 2000 ⁇ , and most preferably of about 1000 ⁇ to 1200 ⁇ may be used to separate smaller RNA molecules, e.g. RNA molecules of about 30-1000, 50-1000 or 100-1000 or 20-200, 20-100, 20-50 or 20-30 nucleotides may also be separated in this way.
  • dextran including e.g. Sephadex® and Sephacryl® materials, agarose, dextran/agarose mixtures, polyacrylamide, etc.
  • the material for the reversed phase is a porous polystyrene polymer, a (non-alkylated) (porous) polystyrenedivinylbenzene polymer, porous silica gel, porous silica gel modified with non-polar residues, particularly porous silica gel modified with alkyl containing residues, more preferably with butyl-, octyl and/or octadecyl containing residues, porous silica gel modified with phenylic residues, porous polymethacrylates, wherein in particular a porous polystyrene polymer or a non-alkylated (porous) polystyrenedivinylbenzene may be used.
  • a non-alkylated porous polystyrenedivinylbenzene which is very particularly preferred for the method according to the invention is one which, without being limited thereto, may have in particular a particle size of 8.0 ⁇ 1.5 ⁇ m, in particular 8.0 ⁇ 0.5 ⁇ m, and a pore size of 1000-1500 ⁇ , in particular 1000-1200 ⁇ or 3500-4500 ⁇ .
  • the method according to the invention is performed as an ion pair method, wherein an ion with a lipophilic residue and positive charge is added to the mobile phase as counterion for the negatively charged RNA.
  • an ion pair with lipophilic character is obtained, which is slowed down by the nonpolar stationary phase of the reversed phase system.
  • the precise conditions for the ion pair method have to be empirically worked out for each specific separation problem.
  • the size of the counterion, its concentration and the pH value of the solution contribute greatly to the separation result. This means that the empirically established conditions of an ion pair method cannot be straightforwardly applied to a different separation problem.
  • Alkylammonium salts such as triethylammonium acetate, and/or tetraalkylammonium compounds, such as tetrabutylammonium, are favourably added in the method according to the invention.
  • 0.1 M triethylammonium acetate is added and the pH value is adjusted to about 7.
  • This buffer for the ion pair method solves the separation problem underlying the present invention, i.e. the purification of RNA on a preparative scale, in a particularly favourable manner.
  • the following may be considered as further buffer solutions: trifluoroacetic acid, acetic acid, formic acid, acetate buffer, phosphate buffer, tetrabutylammonium bisulfate, tetrabutylammonium bromide and tetrabutylammonium chloride.
  • Selection of the mobile phase depends on the type of separation desired. This means that the mobile phase established for a specific separation, as may be known for example from the prior art, cannot be straightforwardly applied to a different separation problem with a sufficient prospect of success. For each separation problem, the ideal elution conditions, in particular the mobile phase used, have to be determined by empirical testing.
  • a mixture of an aqueous solvent and an organic solvent is used as the mobile phase for eluting the RNA.
  • a buffer to be used as the aqueous solvent which has in particular a pH of 6.0-8.0, for example of about 7, for example. 7.0; preferably the buffer is triethylammonium acetate, particularly preferably a 0.02 M to 0.5 M, in particular 0.08 M to 0.12 M, very particularly an about 0.1 M triethylammonium acetate buffer, which, as described above, also acts as a counterion to the RNA in the ion pair method.
  • the organic solvent which is used in the mobile phase is acetonitrile, methanol, ethanol, 1-propanol, 2-propanol and acetone or a mixture thereof, very particularly preferably acetonitrile.
  • acetonitrile is acetonitrile, methanol, ethanol, 1-propanol, 2-propanol and acetone or a mixture thereof, very particularly preferably acetonitrile.
  • the mobile phase it has proven particularly favourable for the method according to the invention for the mobile phase to contain 5.0 vol. % to 25.0 vol. % organic solvent, relative to the mobile phase, and for this to be made up to 100 vol. % with the aqueous solvent.
  • the proportion of organic solvent is increased, in particular by at least 10%, more preferably by at least 50% and most preferably by at least 100%, optionally by at least 200%, relative to the initial vol. % in the mobile phase.
  • the proportion of organic solvent in the mobile phase amounts in the course of HPLC separation to 3 to 9, preferably 4 to 7.5, in particular 5.0 vol. %, in each case relative to the mobile phase.
  • the mobile phase prefferably contains 7.5 vol. % to 17.5 vol. % organic solvent, relative to the mobile phase, and for this to be made up to 100 vol. % with the aqueous buffered solvent.
  • elution may proceed isocratically or by means of gradient separation.
  • elution of the RNA proceeds with a single eluent or a constant mixture of a plurality of eluents, wherein the solvents described above in detail may be used as eluent.
  • gradient separation is performed.
  • the composition of the eluent is varied by means of a gradient program.
  • the equipment necessary for gradient separation is known to a person skilled in the art.
  • Gradient elution may here proceed either on the low pressure side by mixing chambers or on the high pressure side by further pumps.
  • the proportion of organic solvent in the mobile phase may be increased in the course of HPLC separation from 5.0 vol. % to 20.0 vol. %, in each case relative to the mobile phase.
  • the proportion of organic solvent in the mobile phase may be increased in the course of HPLC separation from 7.5 vol. % to 17.5 vol. %, in particular 9.5 to 14.5 vol. %, in each case relative to the mobile phase.
  • purified solvent for HPLC Such purified solvents are commercially obtainable. They may additionally also be filtered with a 1 to 5 ⁇ m microfilter, which is generally mounted in the system upstream of the pump. It is additionally favourable for all the solvents to be degassed prior to use, since otherwise gas bubbles occur in most pumps. If air bubbles occur in the solvent, this may interfere not only with separation but also with the continuous monitoring of outflow in the detector.
  • the solvents may be degassed by heating, by vigorous stirring with a magnetic stirrer, by brief evacuation, by ultrasonication or by passing a small stream of helium through the solvent storage vessel.
  • the flow rate of the eluent is so selected that good separation of the RNA from the other constituents contained in the sample to be investigated takes place.
  • the eluent flow rate selected for the method according to the invention may amount to from 1 ml/min to several litres per minute (in the case of upscaling), in particular about 1 to 1000 ml/min, more preferably 5 ml to 500 ml/min, even more preferably more than 100 ml/min, depending on the type and scope of the upscaling. This flow rate may be established and regulated by the pump.
  • Detection proceeds favourably with a UV detector at 254 nm, wherein a reference measurement may be made at 600 nm.
  • a reference measurement may be made at 600 nm.
  • any other detection method may alternatively be used, with which the RNA described above in greater detail may be detected in satisfactory and reliable manner.
  • RNA-containing eluted solvent quantities For preparative purification of the RNA with the method according to the invention, it is advisable to collect the RNA-containing eluted solvent quantities. In this respect, it is favourable to carry out this collection in such a way that the eluted solvent is collected in individual separated fractions. This may take place for example with a fraction collector. In this way, the high-purity RNA-containing fractions may be separated from other RNA-containing fractions which still contain undesired impurities, albeit in very small quantities. The individual fractions may be collected for example over 1 minute.
  • the method according to the invention is favourably performed under completely denaturing conditions. This may proceed for example in that sample application takes place at a temperature of 4-12° C., the HPLC method otherwise proceeding at a higher temperature, preferably at 70° C. or more, particularly preferably at 75° C. or more, in particular up to 82° C., and very particularly preferably at about 78° C. Heating is typically important for denaturing the RNA, whereby better separation is ultimately achieved. Resolution falls at lower temperatures, i.e. separation of the RNA from the impurities decreases.
  • Sample application may be performed with two methods, stop-flow injection or loop injection.
  • stop-flow injection a microsyringe is used which is able to withstand the high pressure applied in HPLC.
  • the sample is injected through a septum in an inlet valve either directly onto the column packing or onto a small drop of inert material immediately over the packing.
  • the system may in this case be under elevated pressure, or the pump may be turned off prior to injection, which is then performed when the pressure has fallen to close to the normal value.
  • a loop injector is used to introduce the sample. This consists of a tubular loop, into which the sample is inserted.
  • the stationary phase is then conveyed out of the pump through the loop, whose outlet leads directly into the column.
  • the sample is entrained in this way by the stationary phase into the column, without solvent flow to the pump being interrupted.
  • the present invention further provides the use of a porous reversed phase in the above-described HPLC method according to the invention.
  • the porous reversed phase has a particle size of 8.0 ⁇ m to 50 ⁇ m, in particular 8.0 to 30, still more preferably 8.0 to 25 ⁇ m.
  • the reversed phase may be present in bead form.
  • the method according to the invention may be performed particularly favourably with a porous reversed phase with this particle size and/or in the form of beads, wherein particularly good separation results are obtained.
  • the reversed phase used for the use according to the invention is porous, since with stationary reversed phases, which are not porous, and thus differ completely with regard to particle size from the subject matter of the present invention, as described for example by A. Azarani and K. H. Hecker, excessively high pressures are built up, such that preparative purification of the RNA by means of HPLC is possible only with great difficulty, if at all.
  • the reversed phase has a pore size of 1000 ⁇ to 5000 ⁇ , in particular a pore size of 1000 ⁇ to 4000 ⁇ , or the above-stated preferred values.
  • Particularly preferred pore sizes for the reversed phases are 1000-1200 ⁇ and 3500-4500 ⁇ .
  • the material for the reversed phase is a polystyrenedivinylbenzene, wherein in particular non-alkylated polystyrenedivinylbenzene may be used.
  • Stationary phases with polystyrenedivinylbenzene are known per se.
  • the per se known polystyrenedivinylbenzenes already used for HPLC methods, which are commercially obtainable, may be used for the method according to the invention.
  • a non-alkylated porous polystyrenedivinylbenzene which is very particularly preferred for the use according to the invention is one which has in particular a particle size of 8.0 ⁇ 1.5 ⁇ m, in particular 8.0 ⁇ 0.5 ⁇ m, and a pore size of 1000- or 4000 ⁇ .
  • this stationary phase described in greater detail above is located in a column.
  • V2A steel is conventionally used as the material for the column, but other materials may also be used for the column provided they are suitable for the conditions prevailing during HPLC recovery.
  • the column is straight. It is favourable for the HPLC column to have a length of 5 cm to 100 cm and a diameter of 4 mm to 25 mm.
  • Columns used for the method according to the invention may in particular have the following dimensions: 50 mm long and 7.5 mm in diameter or 50 mm long and 4.6 mm in diameter, or 50 mm long and 10 mm in diameter or any other dimension with regard to length and diameter, which is suitable for preparative purification of RNA by means of HPLC, even lengths of several meters and also larger diameters being feasible in the case of upscaling.
  • the dimensions are here geared towards what is technically possible with liquid chromatography.
  • RNA samples in particular the preferred embodiments described in detail hereinafter, exhibits a series of advantages: in the context of the use according to the invention, substantially larger quantities of RNA may be separated than is possible with the methods known from the prior art.
  • the use according to the invention enables these higher quantities to be obtained with a high degree of purity. Separation of degraded fragments or of relatively long fragments or of fragments which have arisen as a result of premature termination of transcription is possible.
  • good separation of further impurities present in RNA samples such as enzymes, for example RNases or polymerases, and nucleotides is possible. These relatively large quantities of RNA may be recovered within minutes, even from samples having a very high level of contamination with impurities.
  • RNA recovery proceeds reliably, i.e. high purity RNA is recovered with great reliability.
  • the use according to the invention enables high resolution to be achieved.
  • the use according to the invention may easily be operated automatically. It is thus most suitable for routine purification of RNA on a preparative scale.
  • RNA is stable under the conditions of the HPLC separation method, i.e. degradation into RNA fragments and thus the occurrence of new impurities or a reduction in the yield of pure RNA during HPLC purification is avoided.
  • FIG. 1 shows a chromatogram of a separation of 10 ⁇ g of luciferase-mRNA (analytical);
  • FIG. 2 shows a chromatogram of a separation of 1.5 ⁇ g of luciferase-mRNA (preparative);
  • FIG. 3 shows the chromatogram of FIG. 2 , the collected fractions being highlighted in grey;
  • FIG. 4 shows verification of the purity of the collected mRNA fractions on an agarose gel
  • FIG. 5 shows a chromatogram of a separation of 200 ⁇ g of a 2 kb and of a 4 kb RNA fragment with a stationary phase, which has a pore size of 1000 ⁇ ;
  • FIG. 6 shows a chromatogram of a separation of 100 ⁇ g of a 2 kb and of a 4 kb RNA fragment with a stationary phase, which has a pore size of 4000 ⁇ ;
  • FIG. 7 shows a chromatogram of a separation of 250 ⁇ g of a 2 kb and of a 4 kb RNA fragment with a stationary matrix, which has a pore size of 4000 ⁇ ,
  • FIG. 8 is a bar chart which demonstrates the improvement in the expression of luciferase from RNA purified with the method according to the invention.
  • FIG. 9 shows the sequence of the wild-type of luciferase, specifically the mRNA sequence, which was used for the exemplary embodiments.
  • FIG. 10 shows a chromatogram of a separation of 3 mg of a Flic(GC) RNA preparation (FC-9050) with a stationary matrix, which has a pore size of 4000 ⁇ ,
  • FIG. 11 shows a chromatogram of a separation of 1.5 mg of a FOLH1(GC) RNA preparation (FO-9334) with a stationary matrix, which has a pore size of 4000 ⁇ ,
  • FIG. 12 shows a chromatogram of a separation of 1.5 mg of a KLK3(GC) RNA preparation (KL-8849) with a stationary matrix, which has a pore size of 4000 ⁇ ,
  • FIG. 13 shows a chromatogram of a separation of 1.5 mg of a PSCA(GC) RNA preparation (PS-8845) with a stationary matrix, which has a pore size of 4000 ⁇ ,
  • FIG. 14 shows a chromatogram of a separation of 1.5 mg of a STEAP(GC) RNA preparation (ST-8848) with a stationary matrix, which has a pore size of 4000 ⁇ ,
  • FIG. 15 shows a chromatogram of a separation of a mixture of a 2 kb RNA (200 ⁇ g) and a 4 kb RNA (200 ⁇ g) with a non-porous stationary matrix;
  • FIG. 16 shows an agarose gel analysis corresponding to the chromatogram according to FIG. 15 , which shows a separation of a mixture of a 2 kb RNA (200 ⁇ g) and a 4 kb RNA (200 ⁇ g) with a non-porous stationary matrix;
  • Luciferase mRNA having a size of 1825 base pairs was used for separation.
  • a porous, non-alkylated polystyrene/divinylbenzene (polystyrenedivinylbenzene) matrix (conventional commercial product from Polymer Laboratories) was used as the stationary phase. It had a particle size of 8 ⁇ m and a pore size of 4000 ⁇ .
  • the column used was 5.0 cm long and had a diameter of 7.5 mm.
  • the sampler temperature was 12° C.
  • the temperature for the HPLC separation, in particular of the separation column was 78° C., i.e. operations were carried out under completely denaturing conditions.
  • Detection proceeded with a UV detector at 254 nm with a reference measurement at 600 nm. Flow rate was 3 ml/min.
  • the purpose of purifying the luciferase mRNA on a preparative scale is to remove these undesired impurities.
  • FIGS. 2 and 3 show the corresponding chromatograms for the separation of luciferase mRNA on a preparative scale (1.5 mg), wherein the gradient program is shown in broken lines in FIG. 2 .
  • the collected fractions 1 to 10 are highlighted in grey in FIGS. 2 and 3 ; the fractions were collected over a period of 1 minute.
  • Fractions 5 to 8 contain the desired luciferase mRNA without undesired impurities. As a result, a separation of the RNA was successful, leading to a highly pure fraction of RNA in preparative scale.
  • This exemplary embodiment shows that, using the method according to the invention, it is possible to purify mRNA on a preparative scale by means of HPLC.
  • RNA fragments 200 ⁇ g of a 2 kb and 4 kb RNA fragment were used for separation.
  • a porous, non-alkylated polystyrene/divinylbenzene matrix (conventional commercial product from Polymer Laboratories) was used as the stationary phase. It had a particle size of 8 ⁇ m and a pore size of 1000 ⁇ .
  • the column used was 2.5 cm long and had a diameter of 4.6 mm.
  • the sampler temperature was 12° C.
  • the temperature for the HPLC separation, in particular of the separation column was 78° C., i.e. operations were carried out under completely denaturing conditions.
  • Detection proceeded with a UV detector at 254 nm with a reference measurement at 600 nm. Flow rate was 3 ml/min.
  • FIG. 5 shows the corresponding chromatograms for this separation on a preparative scale (200 ⁇ g), wherein the gradient program is shown in broken lines in FIG. 5 .
  • the collected fractions are highlighted in grey in FIG. 5 ; the fractions were collected over a period of 1 minute.
  • a separation of the RNA was successful, leading to a highly pure fraction of RNA in preparative scale.
  • RNA fragment 100 ⁇ g of a 2 kb and 4 kb RNA fragment were used for separation.
  • a porous, non-alkylated polystyrene/divinylbenzene matrix (conventional commercial product from Polymer Laboratories) was used as the stationary phase. It had a particle size of 8 ⁇ m and a pore size of 4000 ⁇ .
  • the column used was 2.5 cm long and had a diameter of 4.6 mm.
  • the sampler temperature was 12° C.
  • the temperature for the HPLC separation, in particular of the separation column was 78° C., i.e. operations were carried out under completely denaturing conditions.
  • Detection proceeded with a UV detector at 254 nm with a reference measurement at 600 nm. Flow rate was 3 ml/min.
  • FIG. 6 shows the corresponding chromatograms for this separation on a preparative scale (100 ⁇ g), wherein the gradient program is shown in broken lines in FIG. 6 . The fractions collected are highlighted in grey in FIG. 6 . As a result, a separation of the RNA was successful, leading to a highly pure fraction of RNA in preparative scale.
  • RNA fragment 250 ⁇ g of a 2 kb and 4 kb RNA fragment were used for separation.
  • a porous, non-alkylated polystyrene/divinylbenzene matrix (conventional commercial product from Polymer Laboratories) was used as the stationary phase. It had a particle size of 8 ⁇ m and a pore size of 4000 ⁇ .
  • the column used was 2.5 cm long and had a diameter of 4.6 mm.
  • the sampler temperature was 12° C.
  • the temperature for the HPLC separation, in particular of the separation column was 78° C., i.e. operations were carried out under completely denaturing conditions.
  • Detection proceeded with a UV detector at 254 nm with a reference measurement at 600 nm. Flow rate was 3 ml/min.
  • FIG. 7 shows the corresponding chromatograms for this separation on a preparative scale (250 ⁇ g), wherein the gradient program is shown in broken lines in FIG. 7 . The fractions collected are highlighted in grey in FIG. 7 . As a result, a separation of the RNA was successful, leading to a highly pure fraction of RNA in preparative scale.
  • FIG. 8 The improvement of the expression of luciferase resulting from purification with the method according to the invention is shown in FIG. 8 .
  • Detection proceeded with a UV detector at 254 nm with a reference measurement at 600 nm. Flow rate was 3 ml/min.
  • FIG. 10 shows the corresponding chromatograms for this separation on a preparative scale (3 mg), wherein the gradient program is shown in broken lines in FIG. 10 . The fractions collected are highlighted in grey in FIG. 10 . As can be seen, a separation of the RNA was successful, leading to a highly pure fraction of RNA in preparative scale.
  • a FOLH1 (GC) RNA preparation (FO-9334), 1.5 mg of a KLK3(GC) RNA preparation (KL-8849), 1.5 mg of a PSCA(GC) RNA preparation (PS-8845) or 1.5 mg of a STEAP(GC) RNA preparation (ST-8848) were used for separation.
  • a porous, non-alkylated polystyrene/divinylbenzene matrix (conventional commercial product from Polymer Laboratories) was used as the stationary phase. It had a particle size of 8 ⁇ m and a pore size of 4000 ⁇ .
  • the column used was 2.5 cm long and had a diameter of 4.6 mm.
  • the sampler temperature was 12° C.
  • the temperature for the HPLC separation, in particular of the separation column was 78° C., i.e. operations were carried out under completely denaturing conditions.
  • Detection proceeded with a UV detector at 254 nm with a reference measurement at 600 nm. Flow rate was 3 ml/min.
  • FIGS. 11 , 12 , 13 and 14 shows the corresponding chromatograms for this separation of 1.5 mg of a FOLH1(GC) RNA preparation (FO-9334), 1.5 mg of a KLK3(GC) RNA preparation (KL-8849), 1.5 mg of a PSCA(GC) RNA preparation (PS-8845) or 1.5 mg of a STEAP(GC) RNA preparation (ST-8848), respectively on a preparative scale (1.5 mg), wherein the gradient program is shown in broken lines in these Figures.
  • the fractions collected are highlighted in grey in FIGS. 11 , 12 , 13 and 14 .
  • a separation of the RNAs is possible in each case, leading to a highly pure fraction of RNA in each case in preparative scale.
  • a mixture of 200 ⁇ g of a 2 kb RNA and 200 ⁇ g of a 4 kb RNA were used for separation.
  • the columns used were packed with either a 1000 ⁇ non-alkylated porous polystyrenedivinylbenzene or a non-porous stationary polystyrenedivinylbenzene matrix.
  • the column used for the 1000 ⁇ non-alkylated porous polystyrenedivinylbenzene was 2.5 cm long and had a diameter of 4.6 mm.
  • the column used for the non-alkylated non-porous polystyrenedivinylbenzene was 2.5 cm long and had a diameter of 4.0 mm.
  • the sampler temperature was 12° C.
  • the temperature for the HPLC separation, in particular of the separation column was 78° C., i.e. operations were carried out under completely denaturing conditions.
  • Detection proceeded with a UV detector at 254 nm with a reference measurement at 600 nm. Flow rate was 3 ml/min.
  • FIG. 15 shows the corresponding chromatogram for this separation on a preparative scale (each 200 ⁇ g), wherein the gradient program is shown in broken lines in FIG. 15 . The fractions collected are highlighted in grey in FIG. 15 . As can be seen, a separation of both RNAs is not possible using a common non-alkylated porous polystyrenedivinylbenzene as a matrix.
  • FIG. 16 shows the agarose gel corresponding to the chromatogram according to FIG. 15 .

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
US12/520,172 2006-12-22 2007-12-20 Method for purifying RNA on a preparative scale by means of HPLC Active 2028-10-20 US8383340B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE102006061015.6 2006-12-22
DE102006061015A DE102006061015A1 (de) 2006-12-22 2006-12-22 Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC
DE102006061015 2006-12-22
PCT/EP2007/011294 WO2008077592A1 (en) 2006-12-22 2007-12-20 Method for purifying rna on a preparative scale by means of hplc

Publications (2)

Publication Number Publication Date
US20100048883A1 US20100048883A1 (en) 2010-02-25
US8383340B2 true US8383340B2 (en) 2013-02-26

Family

ID=39186980

Family Applications (1)

Application Number Title Priority Date Filing Date
US12/520,172 Active 2028-10-20 US8383340B2 (en) 2006-12-22 2007-12-20 Method for purifying RNA on a preparative scale by means of HPLC

Country Status (13)

Country Link
US (1) US8383340B2 (de)
EP (1) EP2092064B1 (de)
JP (1) JP5307724B2 (de)
KR (1) KR101183173B1 (de)
CN (1) CN101563457B (de)
AT (1) ATE481482T1 (de)
AU (1) AU2007338360B2 (de)
CA (1) CA2670727C (de)
DE (2) DE102006061015A1 (de)
DK (1) DK2092064T3 (de)
ES (1) ES2352306T3 (de)
PL (1) PL2092064T3 (de)
WO (1) WO2008077592A1 (de)

Cited By (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100189729A1 (en) * 2007-01-09 2010-07-29 Curvac Gmbh Rna-coded antibody
US8664194B2 (en) 2011-12-16 2014-03-04 Moderna Therapeutics, Inc. Method for producing a protein of interest in a primate
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2014186334A1 (en) 2013-05-15 2014-11-20 Robert Kruse Intracellular translation of circular rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US8999380B2 (en) 2012-04-02 2015-04-07 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9107886B2 (en) 2012-04-02 2015-08-18 Moderna Therapeutics, Inc. Modified polynucleotides encoding basic helix-loop-helix family member E41
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9334328B2 (en) 2010-10-01 2016-05-10 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US9428535B2 (en) 2011-10-03 2016-08-30 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US9447431B2 (en) 2012-02-15 2016-09-20 Curevac Ag Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
US9669089B2 (en) 2012-02-15 2017-06-06 Curevac Ag Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
US9683233B2 (en) 2012-03-27 2017-06-20 Curevac Ag Artificial nucleic acid molecules for improved protein or peptide expression
WO2017182524A1 (en) 2016-04-22 2017-10-26 Biontech Rna Pharmaceuticals Gmbh Methods for providing single-stranded rna
US9839697B2 (en) 2010-08-13 2017-12-12 Curevac Ag Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
US9872900B2 (en) 2014-04-23 2018-01-23 Modernatx, Inc. Nucleic acid vaccines
US9890391B2 (en) 2012-03-27 2018-02-13 Curevac Ag RNA vector with an open reading frame, an albumin 3′-UTR, and a histone stem loop
US9974845B2 (en) 2013-02-22 2018-05-22 Curevac Ag Combination of vaccination and inhibition of the PD-1 pathway
US10010592B2 (en) 2012-02-15 2018-07-03 Curevac Ag Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
US10017826B2 (en) 2015-05-08 2018-07-10 Curevac Ag Method for producing RNA
US10034951B1 (en) 2017-06-21 2018-07-31 New England Biolabs, Inc. Use of thermostable RNA polymerases to produce RNAs having reduced immunogenicity
US10047375B2 (en) 2013-12-30 2018-08-14 Curevac Ag Artificial nucleic acid molecules
US10080809B2 (en) 2012-03-27 2018-09-25 Curevac Ag Artificial nucleic acid molecules comprising a 5′TOP UTR
WO2019036683A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. ANALYTICAL METHODS BY HPLC
WO2019036685A1 (en) * 2017-08-18 2019-02-21 Modernatx, Inc. METHODS FOR HPLC ANALYSIS
US10232024B2 (en) 2012-02-15 2019-03-19 Curevac Ag Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
US10307472B2 (en) 2014-03-12 2019-06-04 Curevac Ag Combination of vaccination and OX40 agonists
US10323076B2 (en) 2013-10-03 2019-06-18 Modernatx, Inc. Polynucleotides encoding low density lipoprotein receptor
WO2020072914A1 (en) 2018-10-04 2020-04-09 New England Biolabs, Inc. Methods and compositions for increasing capping efficiency of transcribed rna
US10653712B2 (en) 2016-09-14 2020-05-19 Modernatx, Inc. High purity RNA compositions and methods for preparation thereof
US10815291B2 (en) 2013-09-30 2020-10-27 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
WO2021042135A2 (en) 2019-08-28 2021-03-04 Contamination Source Identification Llc Rapid isolation and collection of microbial rna from a biological specimen
US11028379B1 (en) 2021-01-27 2021-06-08 New England Biolabs, Inc. FCE mRNA capping enzyme compositions, methods and kits
US11072808B2 (en) 2018-10-04 2021-07-27 New England Biolabs, Inc. Methods and compositions for increasing capping efficiency of transcribed RNA
WO2021195212A1 (en) * 2020-03-25 2021-09-30 Waters Technologies Corporation Devices and methods for the sensitive detection and quantitation of biomolecules
US11254951B2 (en) 2014-12-30 2022-02-22 Curevac Ag Artificial nucleic acid molecules
EP4035659A1 (de) 2016-11-29 2022-08-03 PureTech LYT, Inc. Exosome zur ausgabe von therapeutischen wirkstoffen
WO2022164428A1 (en) 2021-01-27 2022-08-04 New England Biolabs, Inc. Faustovirus capping enzyme, mrna capping enzyme compositions, methods and kits
WO2022162027A2 (en) 2021-01-27 2022-08-04 Curevac Ag Method of reducing the immunostimulatory properties of in vitro transcribed rna
WO2022256597A1 (en) 2021-06-04 2022-12-08 Translate Bio, Inc. Assay for quantitative assessment of mrna capping efficiency
WO2023014649A1 (en) 2021-08-02 2023-02-09 Modernatx, Inc. Extraction-less reverse phase (rp) chromatography of mrna encapsulated in lipid nanoparticles for mrna purity assessment
US11667910B2 (en) 2015-05-29 2023-06-06 CureVac Manufacturing GmbH Method for producing and purifying RNA, comprising at least one step of tangential flow filtration
US11697816B2 (en) 2013-12-30 2023-07-11 CureVac SE Artificial nucleic acid molecules
US11739125B2 (en) 2013-08-21 2023-08-29 Cure Vac SE Respiratory syncytial virus (RSV) vaccine
US11761009B2 (en) 2014-12-12 2023-09-19 CureVac SE Artificial nucleic acid molecules for improved protein expression
WO2023196950A1 (en) 2022-04-07 2023-10-12 New England Biolabs, Inc. Methods of higher fidelity rna synthesis
US11786590B2 (en) 2015-11-09 2023-10-17 CureVac SE Rotavirus vaccines
US11865084B2 (en) 2016-12-23 2024-01-09 CureVac SE MERS coronavirus vaccine
WO2024030369A1 (en) 2022-08-01 2024-02-08 Modernatx, Inc. Extraction-less reverse phase (rp) chromatography for mrna purity assessment
US12083190B2 (en) 2013-08-21 2024-09-10 CureVac SE Rabies vaccine
US12161711B2 (en) 2016-12-23 2024-12-10 CureVac SE Lassa virus vaccine
US12168050B2 (en) 2016-05-04 2024-12-17 CureVac SE Compositions comprising a norovirus nucleic acid and methods of use thereof
WO2025019023A1 (en) 2023-07-20 2025-01-23 New England Biolabs, Inc. Polynucleotide error recognition methods and compositions
US12227549B2 (en) 2016-05-04 2025-02-18 CureVac SE RNA encoding a therapeutic protein
WO2025059500A1 (en) 2023-09-14 2025-03-20 New England Biolabs, Inc. Rna polymerases
WO2025072696A1 (en) 2023-09-29 2025-04-03 New England Biolabs, Inc. Compositions, methods, and cells for making 2-aminoadenine (dz) dna
US12329811B2 (en) 2021-01-11 2025-06-17 Modernatx, Inc. Seasonal RNA influenza virus vaccines
US12337031B2 (en) 2013-08-21 2025-06-24 CureVac SE Combination vaccine
WO2025137453A1 (en) 2023-12-20 2025-06-26 New England Biolabs, Inc. Compositions, methods, kits, and instruments for analyzing rna structure
US12385088B2 (en) 2017-12-21 2025-08-12 CureVac SE Linear double stranded DNA coupled to a single support or a tag and methods for producing said linear double stranded DNA
WO2025208142A2 (en) 2024-03-29 2025-10-02 New England Biolabs, Inc. Compositions, kits, and methods for in vitro transcription
WO2025213179A1 (en) 2024-04-05 2025-10-09 New England Biolabs, Inc. Compositions and methods for characterizing rna
WO2025227034A1 (en) 2024-04-26 2025-10-30 New England Biolabs, Inc. Salt active nuclease compositions and methods
US12460259B2 (en) 2019-03-11 2025-11-04 Modernatx, Inc. Fed-batch in vitro transcription process
WO2026010863A2 (en) 2024-07-01 2026-01-08 New England Biolabs, Inc. Programmable cleavage of rna
US12529047B1 (en) 2021-12-21 2026-01-20 Modernatx, Inc. mRNA quantification methods
US12528855B2 (en) 2018-12-14 2026-01-20 CureVac SE KRAS variant mRNA molecules
US12533422B2 (en) 2013-11-01 2026-01-27 CureVac SE Modified RNA with decreased immunostimulatory properties

Families Citing this family (187)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
WO2009046739A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating prostate cancer (pca)
WO2009046738A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
WO2010033652A1 (en) * 2008-09-17 2010-03-25 Ge Healthcare Bio-Sciences Corp. Method for small rna isolation
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
WO2011069529A1 (en) 2009-12-09 2011-06-16 Curevac Gmbh Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
ES2558106T3 (es) 2010-07-30 2016-02-02 Curevac Ag Formación de complejos de ácidos nucleicos con componentes catiónicos disulfuro-reticulados para la transfección e inmunoestimulación
WO2012089225A1 (en) 2010-12-29 2012-07-05 Curevac Gmbh Combination of vaccination and inhibition of mhc class i restricted antigen presentation
WO2012116715A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in newborns and infants
WO2012113413A1 (en) 2011-02-21 2012-08-30 Curevac Gmbh Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
WO2012116714A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
WO2013113326A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
MX2015011944A (es) 2013-03-14 2015-12-01 Shire Human Genetic Therapies Evaluacion cuantitativa para la eficacia de los casquetes de arn mensajero.
EP2983804A4 (de) 2013-03-15 2017-03-01 Moderna Therapeutics, Inc. Ionenaustauschreinigung von mrna
JP6461830B2 (ja) 2013-03-15 2019-01-30 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｒｎａ精製方法
WO2014152031A1 (en) * 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Ribonucleic acid purification
US10077439B2 (en) 2013-03-15 2018-09-18 Modernatx, Inc. Removal of DNA fragments in mRNA production process
US20160017313A1 (en) * 2013-03-15 2016-01-21 Moderna Therapeutics, Inc. Analysis of mrna heterogeneity and stability
US10138507B2 (en) 2013-03-15 2018-11-27 Modernatx, Inc. Manufacturing methods for production of RNA transcripts
RS62529B1 (sr) 2013-07-11 2021-11-30 Modernatx Inc Kompozicije koje sadrže sintetičke polinukleotide koji kodiraju proteine povezane sa crispr i sintetičke sgrnk i postupci upotrebe
SG11201510747RA (en) 2013-08-21 2016-03-30 Curevac Ag Method for increasing expression of rna-encoded proteins
EP3450561A1 (de) 2013-08-21 2019-03-06 CureVac AG Verfahren zur erhöhung der expression von rna-codierten proteinen
EP3461498A1 (de) 2013-08-21 2019-04-03 CureVac AG Tollwutimpfstoff
EP3586871A3 (de) 2013-08-21 2020-03-11 CureVac AG Impfstoff gegen das respiratorische synzytialvirus
EP3052511A4 (de) 2013-10-02 2017-05-31 Moderna Therapeutics, Inc. Polynukleotidmoleküle und verwendungen davon
EP3542802A1 (de) 2013-11-01 2019-09-25 CureVac AG Modifizierte rna mit verminderten immunstimulierenden eigenschaften
EP3540060A1 (de) 2013-12-30 2019-09-18 CureVac AG Verfahren zur rna-analyse
SG11201604198YA (en) 2013-12-30 2016-07-28 Curevac Ag Methods for rna analysis
CA2936286A1 (en) 2014-04-01 2015-10-08 Curevac Ag Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
RU2738753C2 (ru) 2014-06-10 2020-12-16 Куревак Риэл Эстейт Гмбх Способы и средства повышения продуктивности рнк
EP3157573A4 (de) 2014-06-19 2018-02-21 Moderna Therapeutics, Inc. Alternative nukleinsäuremoleküle und verwendungen davon
US10407683B2 (en) 2014-07-16 2019-09-10 Modernatx, Inc. Circular polynucleotides
US10653768B2 (en) 2015-04-13 2020-05-19 Curevac Real Estate Gmbh Method for producing RNA compositions
CN107567497A (zh) 2015-04-17 2018-01-09 库瑞瓦格股份公司 Rna的冻干
DK3326641T3 (da) 2015-04-22 2019-09-30 Curevac Ag Rna-holdig sammensætning til behandling af tumorsygdomme
WO2016174271A1 (en) 2015-04-30 2016-11-03 Curevac Ag Immobilized poly(n)polymerase
ES2875589T3 (es) 2015-05-15 2021-11-10 Curevac Ag Regímenes de sensibilización-refuerzo que implican la administración de al menos un constructo de ARNm
SG11201708540VA (en) 2015-05-20 2017-12-28 Curevac Ag Dry powder composition comprising long-chain rna
CN107530448A (zh) 2015-05-20 2018-01-02 库瑞瓦格股份公司 包含长链rna的干粉组合物
EP4098743A1 (de) 2015-05-29 2022-12-07 CureVac AG Verfahren zum hinzufügen von kappenstrukturen zu rns mittels immobilisierter enzyme
WO2017001058A1 (en) * 2015-07-01 2017-01-05 Curevac Ag Method for analysis of an rna molecule
US10501768B2 (en) 2015-07-13 2019-12-10 Curevac Ag Method of producing RNA from circular DNA and corresponding template DNA
KR102645398B1 (ko) 2015-08-28 2024-03-07 큐어백 에스이 신규 인공 핵산 분자
DK3350333T3 (da) 2015-09-17 2022-01-31 Modernatx Inc Polynukleotider, der indeholder en stabiliserende haleregion
ES2910425T3 (es) 2015-09-17 2022-05-12 Modernatx Inc Compuestos y composiciones para la administración intracelular de agentes terapéuticos
US11434486B2 (en) 2015-09-17 2022-09-06 Modernatx, Inc. Polynucleotides containing a morpholino linker
EP3362576A1 (de) 2015-10-12 2018-08-22 CureVac AG Automatisiertes verfahren zur isolierung, auswahl und/oder bestimmung von mikroorganismen oder zellen in einer lösung
WO2017066789A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Mrna cap analogs with modified sugar
WO2017066791A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Sugar substituted mrna cap analogs
WO2017066781A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Mrna cap analogs with modified phosphate linkage
JP2018530587A (ja) 2015-10-16 2018-10-18 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． ｍＲＮＡキャップ類似体およびｍＲＮＡキャッピングの方法
WO2017066782A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Hydrophobic mrna cap analogs
EP4582098A3 (de) 2015-11-09 2025-12-24 CureVac SE Optimierte nukleinsäuremoleküle
CA3007297A1 (en) 2015-12-22 2017-06-29 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
JP6949845B2 (ja) 2015-12-22 2021-10-13 キュアバック アーゲー Ｒｎａ分子組成物の作製方法
US11248223B2 (en) 2015-12-23 2022-02-15 Curevac Ag Method of RNA in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof
US20210180106A1 (en) 2016-02-12 2021-06-17 Curevac Ag Method for analyzing rna
US20190049414A1 (en) 2016-02-15 2019-02-14 Curevac Ag Method for analyzing by-products of rna in vitro transcription
US11723967B2 (en) 2016-02-17 2023-08-15 CureVac SE Zika virus vaccine
EP3423595A1 (de) 2016-03-03 2019-01-09 CureVac AG Rns-analyse durch gesamthydrolyse
US20190343942A1 (en) 2016-04-22 2019-11-14 Curevac Ag Rna encoding a tumor antigen
WO2017186928A1 (en) 2016-04-29 2017-11-02 Curevac Ag Rna encoding an antibody
WO2017191258A1 (en) 2016-05-04 2017-11-09 Curevac Ag Influenza mrna vaccines
WO2017212007A1 (en) 2016-06-09 2017-12-14 Curevac Ag Cationic carriers for nucleic acid delivery
WO2017212006A1 (en) 2016-06-09 2017-12-14 Curevac Ag Hybrid carriers for nucleic acid cargo
CN109475640B (zh) 2016-06-09 2023-03-10 库瑞瓦格欧洲公司 核酸被运载物的混合载运体
AU2017286606A1 (en) 2016-06-14 2018-12-13 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
WO2017223176A1 (en) 2016-06-24 2017-12-28 Modernatx, Inc. Methods and apparatus for filtration
SG10201913631TA (en) 2016-08-19 2020-03-30 Curevac Ag Rna for cancer therapy
WO2018041921A1 (en) 2016-08-31 2018-03-08 Curevac Ag Mixing device for the production of a liquid nucleic acid composition
KR20190093816A (ko) 2016-10-26 2019-08-26 큐어백 아게 지질 나노입자 mRNA 백신
EP3538067A1 (de) 2016-11-08 2019-09-18 Modernatx, Inc. Stabilisierte formulierungen von lipidnanopartikeln
WO2018096179A1 (en) * 2016-11-28 2018-05-31 Curevac Ag Method for purifying rna
EP3551230A1 (de) 2016-12-08 2019-10-16 CureVac AG Rna zur behandlung oder prophylaxe einer lebererkrankung
WO2018104540A1 (en) 2016-12-08 2018-06-14 Curevac Ag Rnas for wound healing
WO2018111967A1 (en) 2016-12-13 2018-06-21 Modernatx, Inc. Rna affinity purification
WO2018115507A2 (en) 2016-12-23 2018-06-28 Curevac Ag Henipavirus vaccine
WO2018141371A1 (en) 2017-01-31 2018-08-09 Curevac Ag Purification and/or formulation of rna
RS63953B1 (sr) 2017-03-15 2023-02-28 Modernatx Inc Jedinjenje i kompozicije za intracelularnu isporuku terapeutskih sredstava
JP7332478B2 (ja) 2017-03-15 2023-08-23 モデルナティエックス インコーポレイテッド 脂質ナノ粒子製剤
JP2020514370A (ja) 2017-03-17 2020-05-21 キュアバック アーゲー 組合せ抗癌療法のためのｒｎａワクチン及び免疫チェックポイント阻害剤
CN110914433A (zh) 2017-03-24 2020-03-24 库尔维科公司 编码crispr相关蛋白质的核酸及其用途
US11357856B2 (en) 2017-04-13 2022-06-14 Acuitas Therapeutics, Inc. Lipids for delivery of active agents
EP3625363A1 (de) 2017-05-17 2020-03-25 CureVac Real Estate GmbH Verfahren zur bestimmung von wenigstens einem qualitätsparameter einer rna-probe
US12077501B2 (en) 2017-06-14 2024-09-03 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
EP3638215A4 (de) 2017-06-15 2021-03-24 Modernatx, Inc. Rna-formulierungen
EP3424524B1 (de) 2017-07-04 2024-12-11 CureVac SE Rna-impfstoff gegen krebs
US20200362382A1 (en) 2017-08-18 2020-11-19 Modernatx, Inc. Methods of preparing modified rna
US11602557B2 (en) 2017-08-22 2023-03-14 Cure Vac SE Bunyavirales vaccine
MX2020002348A (es) 2017-08-31 2020-10-08 Modernatx Inc Métodos de elaboración de nanopartículas lipídicas.
US11692002B2 (en) 2017-11-08 2023-07-04 CureVac SE RNA sequence adaptation
US11931406B2 (en) 2017-12-13 2024-03-19 CureVac SE Flavivirus vaccine
WO2019193183A2 (en) 2018-04-05 2019-10-10 Curevac Ag Novel yellow fever nucleic acid molecules for vaccination
EP4227319B1 (de) 2018-04-17 2025-11-26 CureVac SE Neuartige rsv-rna-moleküle und zusammensetzungen zur impfung
EP3813874A1 (de) 2018-06-27 2021-05-05 CureVac AG Neuartige lassa-virus-rna-moleküle und zusammensetzungen zur impfung
CA3102135A1 (en) 2018-06-28 2020-01-02 Curevac Ag Bioreactor for rna in vitro transcription
JP7410135B2 (ja) 2018-09-19 2024-01-09 モデルナティエックス インコーポレイテッド 治療薬の細胞内送達のための化合物及び組成物
WO2020061457A1 (en) 2018-09-20 2020-03-26 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
US12492425B2 (en) 2018-12-21 2025-12-09 CureVac SE Methods for RNA analysis
WO2020128031A2 (en) 2018-12-21 2020-06-25 Curevac Ag Rna for malaria vaccines
KR20210133218A (ko) 2019-01-31 2021-11-05 모더나티엑스, 인크. 볼텍스 믹서 및 연계된 방법, 시스템 및 이의 장치
BR112021014845A2 (pt) 2019-01-31 2021-11-03 Modernatx Inc Métodos de preparação de nanopartículas lipídicas
EP3920950A1 (de) 2019-02-08 2021-12-15 CureVac AG In den suprachoroidalen raum verabreichte codierende rna zur behandlung von augenerkrankungen
EP3986452A1 (de) 2019-06-18 2022-04-27 CureVac AG Rotavirus-mrna-impfstoff
AU2020328855A1 (en) 2019-08-14 2022-03-03 CureVac SE RNA combinations and compositions with decreased immunostimulatory properties
EP4076647A1 (de) 2019-12-20 2022-10-26 CureVac AG Lipidnanopartikel zur verabreichung von nukleinsäuren
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
DE202021003575U1 (de) 2020-02-04 2022-01-17 Curevac Ag Coronavirus-Vakzine
US11241493B2 (en) 2020-02-04 2022-02-08 Curevac Ag Coronavirus vaccine
CN117003658B (zh) 2020-04-09 2025-10-14 苏州艾博生物科技有限公司 脂质纳米颗粒组合物
WO2021204179A1 (en) 2020-04-09 2021-10-14 Suzhou Abogen Biosciences Co., Ltd. Nucleic acid vaccines for coronavirus
WO2021229502A1 (en) 2020-05-15 2021-11-18 Crispr Therapeutics Ag Messenger rna encoding cas9 for use in genome-editing systems
BR112022024248A2 (pt) 2020-05-29 2023-10-10 CureVac SE Vacinas de combinação à base de ácido nucleico
US20240288407A1 (en) 2020-06-15 2024-08-29 CureVac SE Analysis of nucleic acid mixtures
CN114206463B (zh) 2020-06-30 2024-06-11 苏州艾博生物科技有限公司 脂质化合物和脂质纳米颗粒组合物
US20230272052A1 (en) 2020-07-31 2023-08-31 CureVac SE Nucleic acid encoded antibody mixtures
KR20230054672A (ko) 2020-08-20 2023-04-25 쑤저우 아보젠 바이오사이언시스 컴퍼니 리미티드 지질 화합물 및 지질 나노입자 조성물
EP4157344A2 (de) 2020-08-31 2023-04-05 CureVac SE Coronavirus-impfstoffe auf basis multivalenter nukleinsäuren
US20240246056A1 (en) 2020-09-01 2024-07-25 CureVac RNA Printer GmbH Manufacturing device for a pharmaceutical product
WO2022112498A1 (en) 2020-11-27 2022-06-02 CureVac RNA Printer GmbH A device for preparing a dna product by means of capillary polymerase chain reaction
WO2022137133A1 (en) 2020-12-22 2022-06-30 Curevac Ag Rna vaccine against sars-cov-2 variants
CA3171051A1 (en) 2020-12-22 2022-06-30 Curevac Ag Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
US11918643B2 (en) 2020-12-22 2024-03-05 CureVac SE RNA vaccine against SARS-CoV-2 variants
WO2022152141A2 (en) 2021-01-14 2022-07-21 Suzhou Abogen Biosciences Co., Ltd. Polymer conjugated lipid compounds and lipid nanoparticle compositions
WO2022152109A2 (en) 2021-01-14 2022-07-21 Suzhou Abogen Biosciences Co., Ltd. Lipid compounds and lipid nanoparticle compositions
WO2022200575A1 (en) 2021-03-26 2022-09-29 Glaxosmithkline Biologicals Sa Immunogenic compositions
EP4312988A2 (de) 2021-03-31 2024-02-07 CureVac SE Spritzen mit pharmazeutischen zusammensetzungen mit rna
CA3171589A1 (en) 2021-05-03 2022-11-03 Moritz THRAN Improved nucleic acid sequence for cell type specific expression
US20220364078A1 (en) * 2021-05-14 2022-11-17 Crispr Therapeutics Ag Mrna large scale synthesis and purification
CA3211623A1 (en) 2021-05-24 2022-12-01 Bo YING Lipid compounds and lipid nanoparticle compositions
US20250002524A1 (en) 2021-07-30 2025-01-02 CureVac SE Cap analogs having an acyclic linker to the guanine derivative nucleobase
US20240342206A1 (en) 2021-07-30 2024-10-17 CureVac SE mRNAS FOR TREATMENT OR PROPHYLAXIS OF LIVER DISEASES
WO2023031392A2 (en) 2021-09-03 2023-03-09 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine
JP2024538489A (ja) 2021-09-03 2024-10-23 キュアバック エスイー 核酸を送達するための新規な脂質ナノ粒子
CN118317944A (zh) 2021-09-14 2024-07-09 雷纳嘉德医疗管理公司 非环状脂质及其使用方法
TW202328067A (zh) 2021-09-14 2023-07-16 美商雷納嘉德醫療管理公司 環狀脂質及其使用方法
KR102646914B1 (ko) * 2021-10-01 2024-03-12 서울대학교산학협력단 아실글리세롤 이성질체 및 자유지방산 직접 동시분석법 및 이를 통한 라이페이스 입체선택성 분석법
AR127312A1 (es) 2021-10-08 2024-01-10 Suzhou Abogen Biosciences Co Ltd Compuestos lipídicos ycomposiciones de nanopartículas lipídicas
JP2024536406A (ja) 2021-10-08 2024-10-04 スージョウ・アボジェン・バイオサイエンシズ・カンパニー・リミテッド 脂質化合物及び脂質ナノ粒子組成物
CN116064598B (zh) 2021-10-08 2024-03-12 苏州艾博生物科技有限公司 冠状病毒的核酸疫苗
US20250027108A1 (en) 2021-10-29 2025-01-23 CureVac SE Improved circular rna for expressing therapeutic proteins
WO2023122752A1 (en) 2021-12-23 2023-06-29 Renagade Therapeutics Management Inc. Constrained lipids and methods of use thereof
CA3241492A1 (en) 2021-12-23 2023-06-29 Suzhou Abogen Biosciences Co., Ltd. Lipid compound and lipid nanoparticle composition
EP4469091A1 (de) 2022-01-28 2024-12-04 CureVac SE Nukleinsäure-kodierte transkriptionsfaktor-inhibitoren
AU2023251104A1 (en) 2022-04-07 2024-10-17 Renagade Therapeutics Management Inc. Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents
EP4504252A2 (de) 2022-04-08 2025-02-12 Flagship Pioneering Innovations VII, LLC Impfstoffe und zugehörige verfahren
KR20250028547A (ko) 2022-05-25 2025-02-28 큐어백 에스이 대장균 FimH 항원성 폴리펩타이드를 인코딩하는 핵산 기반 백신
CN115287282B (zh) * 2022-07-27 2025-09-16 苏州纳微科技股份有限公司 一种mRNA工业化分离纯化方法及其应用
JP2025525778A (ja) 2022-08-01 2025-08-07 フラッグシップ パイオニアリング イノベーションズ セブン，エルエルシー 免疫調節タンパク質及び関連方法
WO2024037578A1 (en) 2022-08-18 2024-02-22 Suzhou Abogen Biosciences Co., Ltd. Composition of lipid nanoparticles
EP4593875A1 (de) 2022-09-26 2025-08-06 GlaxoSmithKline Biologicals S.A. Impfstoffe gegen influenzavirus
US12186389B2 (en) 2022-10-28 2025-01-07 Glaxosmithkline Biologicals Sa Nucleic acid base vaccine against emerging SARS-CoV-2 variants
WO2024089229A1 (en) 2022-10-28 2024-05-02 CureVac SE Improved formulations comprising lipid-based carriers encapsulating rna
EP4648794A2 (de) 2023-01-09 2025-11-19 Flagship Pioneering Innovations VII, LLC Impfstoffe und zugehörige verfahren
EP4658664A1 (de) 2023-01-31 2025-12-10 CureVac SE Cap-analoga mit 5'-terminalem acyclischem guanosinderivat
EP4658239A1 (de) 2023-02-03 2025-12-10 GlaxoSmithKline Biologicals S.A. Rna-formulierung
TW202438515A (zh) 2023-02-06 2024-10-01 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 免疫調節組合物及相關方法
GB202302092D0 (en) 2023-02-14 2023-03-29 Glaxosmithkline Biologicals Sa Analytical method
CN115774075B (zh) * 2023-02-15 2023-06-06 江苏耀海生物制药有限公司 一种基于RP-HPLC分析体外转录产物成分circRNA的方法
AU2024233180A1 (en) 2023-03-08 2025-09-25 CureVac SE Novel lipid nanoparticle formulations for delivery of nucleic acids
WO2024192291A1 (en) 2023-03-15 2024-09-19 Renagade Therapeutics Management Inc. Delivery of gene editing systems and methods of use thereof
EP4680595A2 (de) 2023-03-15 2026-01-21 Renagade Therapeutics Management Inc. Lipidnanopartikel mit codierenden rna-molekülen zur verwendung bei der geneditierung und als impfstoffe und therapeutika
WO2024223724A1 (en) 2023-04-27 2024-10-31 Glaxosmithkline Biologicals Sa Influenza virus vaccines
WO2024223728A1 (en) 2023-04-27 2024-10-31 Glaxosmithkline Biologicals Sa Influenza virus vaccines
WO2024235451A1 (en) 2023-05-16 2024-11-21 CureVac RNA Printer GmbH Improved rna in vitro transcription using dna beads
DE112024002330T5 (de) 2023-05-26 2026-03-19 CureVac SE Krebsantigene
WO2024258829A1 (en) 2023-06-12 2024-12-19 Flagship Pioneering Innovations Vii, Llc Sars-cov-2 vaccine compositions and related methods
KR20260025139A (ko) 2023-06-14 2026-02-23 사노피 백신즈 유에스 인크. 메신저 rna의 캡핑 및 테일링 변형을 동시에 식별하거나 정량화하는 방법
WO2024260570A1 (en) 2023-06-23 2024-12-26 CureVac SE Nucleic acid encoded antibodies
WO2025027060A1 (en) 2023-07-31 2025-02-06 CureVac SE Nucleic acid encoded runx3 transcription factor
AU2024335327A1 (en) 2023-09-01 2026-03-26 Renagade Therapeutics Management Inc. Gene editing systems, compositions, and methods for treatment of vexas syndrome
WO2025054236A2 (en) 2023-09-06 2025-03-13 Flagship Pioneering Innovations Vii, Llc Sars-cov-2 vaccine compositions and related methods
WO2025072331A1 (en) 2023-09-26 2025-04-03 Flagship Pioneering Innovations Vii, Llc Cas nucleases and related methods
WO2025081042A1 (en) 2023-10-12 2025-04-17 Renagade Therapeutics Management Inc. Nickase-retron template-based precision editing system and methods of use
WO2025088088A1 (en) 2023-10-27 2025-05-01 CureVac SE Rna composition for improving cell therapy
WO2025103803A1 (en) 2023-11-13 2025-05-22 CureVac SE Immunotherapy against neuronal and brain tumors
WO2025117877A2 (en) 2023-12-01 2025-06-05 Flagship Pioneering Innovations Vii, Llc Cas nucleases and related methods
WO2025128871A2 (en) 2023-12-13 2025-06-19 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2025132839A1 (en) 2023-12-21 2025-06-26 Glaxosmithkline Biologicals Sa Influenza virus vaccines
WO2025155753A2 (en) 2024-01-17 2025-07-24 Renagade Therapeutics Management Inc. Improved gene editing system, guides, and methods
WO2025160334A1 (en) 2024-01-26 2025-07-31 Flagship Pioneering Innovations Vii, Llc Immunoreceptor inhibitory proteins and related methods
WO2025174765A1 (en) 2024-02-12 2025-08-21 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
GB202404607D0 (en) 2024-03-29 2024-05-15 Glaxosmithkline Biologicals Sa RNA formulation
US20250353881A1 (en) 2024-05-16 2025-11-20 Flagship Pioneering Innovations Vii, Llc Immunoreceptor inhibitory proteins and related methods
WO2025245111A1 (en) 2024-05-22 2025-11-27 Flagship Pioneering Innovations Vii, Llc Immunoreceptor targeting proteins and related methods
WO2025242815A1 (en) 2024-05-23 2025-11-27 CureVac SE Immunotherapy of squamous cell carcinoma

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2468048A1 (en) 1994-02-23 1995-08-31 Pamela Pavco Process for purifying chemically synthesized rna
US5447922A (en) 1994-08-24 1995-09-05 Bristol-Myers Squibb Company α-phosphonosulfinic squalene synthetase inhibitors
WO2001046687A2 (en) 1999-12-22 2001-06-28 Transgenomic, Inc. System and method for automated matched ion polynucleotide chromatography
US20020102563A1 (en) 1998-04-24 2002-08-01 Gjerde Douglas T. Apparatus and method for separating and purifying polynucleotides
US20050011836A1 (en) 2003-07-17 2005-01-20 Brian Bidlingmeyer Additives for reversed-phase HPLC mobile phases
US20050215777A1 (en) * 2002-07-12 2005-09-29 Sirna Therapeutics, Inc. Deprotection and purification of oligonucleotides and their derivatives
US20080033158A1 (en) * 2006-08-03 2008-02-07 Chemistry And Technology For Genes, Inc Multi layer chromatography of nucleic acids
US20100189729A1 (en) * 2007-01-09 2010-07-29 Curvac Gmbh Rna-coded antibody
US20100203076A1 (en) * 2007-09-04 2010-08-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2468048A1 (en) 1994-02-23 1995-08-31 Pamela Pavco Process for purifying chemically synthesized rna
US5447922A (en) 1994-08-24 1995-09-05 Bristol-Myers Squibb Company α-phosphonosulfinic squalene synthetase inhibitors
JPH0873477A (ja) 1994-08-24 1996-03-19 Bristol Myers Squibb Co α−ホスホノスルフィネートスクアレンシンセターゼインヒビターおよび方法
US20020102563A1 (en) 1998-04-24 2002-08-01 Gjerde Douglas T. Apparatus and method for separating and purifying polynucleotides
WO2001046687A2 (en) 1999-12-22 2001-06-28 Transgenomic, Inc. System and method for automated matched ion polynucleotide chromatography
US20050215777A1 (en) * 2002-07-12 2005-09-29 Sirna Therapeutics, Inc. Deprotection and purification of oligonucleotides and their derivatives
US20050011836A1 (en) 2003-07-17 2005-01-20 Brian Bidlingmeyer Additives for reversed-phase HPLC mobile phases
US20080033158A1 (en) * 2006-08-03 2008-02-07 Chemistry And Technology For Genes, Inc Multi layer chromatography of nucleic acids
US20100189729A1 (en) * 2007-01-09 2010-07-29 Curvac Gmbh Rna-coded antibody
US20100203076A1 (en) * 2007-09-04 2010-08-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
Anderson, A.C. et al., "HPLC Purification of RNA for Crystallography and NMR." RNA, vol. 2, No. 2, 1996, pp. 110-117.
Azarani, A. et al., "RNA ANalysis by Ion-Pair Reversed-Phase High Performance Liquid Chromatography." Nucleic Acids Research, vol. 29, No. 2, Jan. 15, 2001, p. E7.
Dickman, M.J. et al., "Enrichment and Analysis of RNA Centered on Ion Pair Reverse Phase Methodolo." RNA, vol. 12, No. 4, Apr. 2006, pp. 691-696.
Georgopoulos, D.E., et al.: "Use of High-Performance Liquid Chromatographic Fractionation of Large RNA Molecules in the Assay of Group 1 Intron Ribozyme Activity," J. Chromatogr A, vol. 868(1), pp. 109-114, 2000.
Hashimoto: "Macroporous Synthetic Hydophilic Resin-Based Packings for the Separation of Biopolymers," J. Chromatogr, vol. 544, pp. 249-255, 1991.
McFarland et al., Separation of oligo-RNA by reverse-phase HPLC.Nucleic Acids Research 7(4) : 1067 (1979). *
Petro, et al., Molded continuous poly(styrene-co-divinylbenzene) rod as a separation medium for the very fast separation of polymers. Comparison of the chromatographic properties of the monolithic rod with columns packed with porous and non-porous beads in high-performance liquid chromatography of polystyrenes J. Chromatogr. A, Nov. 1, 1996, 752(1-2): 59-66.
Wincott et al., Synthesis, deprotection, analysis and purification of RNA and ribozymes. Nucleic Acids Research 23(14):2677 (1995). *
Zou et al., Engineered RNase P ribozymes are efficient in cleaving a human cytomegalovirus mRNA in vitro and are effective in inhibiting viral gene expression and growth in human cells. J. of Biological Chemistry 278 (39) :37265 (2003). *

Cited By (163)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100189729A1 (en) * 2007-01-09 2010-07-29 Curvac Gmbh Rna-coded antibody
US11421038B2 (en) 2007-01-09 2022-08-23 Curevac Ag RNA-coded antibody
US9447164B2 (en) 2010-08-06 2016-09-20 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9181319B2 (en) 2010-08-06 2015-11-10 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9937233B2 (en) 2010-08-06 2018-04-10 Modernatx, Inc. Engineered nucleic acids and methods of use thereof
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9839697B2 (en) 2010-08-13 2017-12-12 Curevac Ag Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
US12109275B2 (en) 2010-08-13 2024-10-08 CureVac SE Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded protein
US10653799B2 (en) 2010-08-13 2020-05-19 Curevac Ag Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded protein
US9701965B2 (en) 2010-10-01 2017-07-11 Modernatx, Inc. Engineered nucleic acids and methods of use thereof
US10064959B2 (en) 2010-10-01 2018-09-04 Modernatx, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US9334328B2 (en) 2010-10-01 2016-05-10 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US9657295B2 (en) 2010-10-01 2017-05-23 Modernatx, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US9533047B2 (en) 2011-03-31 2017-01-03 Modernatx, Inc. Delivery and formulation of engineered nucleic acids
US9950068B2 (en) 2011-03-31 2018-04-24 Modernatx, Inc. Delivery and formulation of engineered nucleic acids
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
US10022425B2 (en) 2011-09-12 2018-07-17 Modernatx, Inc. Engineered nucleic acids and methods of use thereof
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US10751386B2 (en) 2011-09-12 2020-08-25 Modernatx, Inc. Engineered nucleic acids and methods of use thereof
US9428535B2 (en) 2011-10-03 2016-08-30 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US9271996B2 (en) 2011-12-16 2016-03-01 Moderna Therapeutics, Inc. Formulation and delivery of PLGA microspheres
US9186372B2 (en) 2011-12-16 2015-11-17 Moderna Therapeutics, Inc. Split dose administration
US8664194B2 (en) 2011-12-16 2014-03-04 Moderna Therapeutics, Inc. Method for producing a protein of interest in a primate
US8680069B2 (en) 2011-12-16 2014-03-25 Moderna Therapeutics, Inc. Modified polynucleotides for the production of G-CSF
US8754062B2 (en) 2011-12-16 2014-06-17 Moderna Therapeutics, Inc. DLIN-KC2-DMA lipid nanoparticle delivery of modified polynucleotides
US9295689B2 (en) 2011-12-16 2016-03-29 Moderna Therapeutics, Inc. Formulation and delivery of PLGA microspheres
US10682406B2 (en) 2012-02-15 2020-06-16 Curevac Ag Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
US11110156B2 (en) 2012-02-15 2021-09-07 Curevac Ag Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
US10912826B2 (en) 2012-02-15 2021-02-09 Curevac Ag Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
US10898589B2 (en) 2012-02-15 2021-01-26 Cure Vac AG Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
US10799577B2 (en) 2012-02-15 2020-10-13 Curevac Ag Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
US9669089B2 (en) 2012-02-15 2017-06-06 Curevac Ag Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
US10610605B2 (en) 2012-02-15 2020-04-07 Curevac Ag Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
US10232024B2 (en) 2012-02-15 2019-03-19 Curevac Ag Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
US9447431B2 (en) 2012-02-15 2016-09-20 Curevac Ag Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
US12201680B2 (en) 2012-02-15 2025-01-21 CureVac SE Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
US10166283B2 (en) 2012-02-15 2019-01-01 Curevac Ag Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
US10111968B2 (en) 2012-02-15 2018-10-30 Curevac Ag Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
US10010592B2 (en) 2012-02-15 2018-07-03 Curevac Ag Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
US12460204B2 (en) 2012-03-27 2025-11-04 CureVac SE Artificial nucleic acid molecules for improved protein or peptide expression
US10080809B2 (en) 2012-03-27 2018-09-25 Curevac Ag Artificial nucleic acid molecules comprising a 5′TOP UTR
US10738306B2 (en) 2012-03-27 2020-08-11 Curevac Ag Artificial nucleic acid molecules for improved protein or peptide expression
US9890391B2 (en) 2012-03-27 2018-02-13 Curevac Ag RNA vector with an open reading frame, an albumin 3′-UTR, and a histone stem loop
US9683233B2 (en) 2012-03-27 2017-06-20 Curevac Ag Artificial nucleic acid molecules for improved protein or peptide expression
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9221891B2 (en) 2012-04-02 2015-12-29 Moderna Therapeutics, Inc. In vivo production of proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9814760B2 (en) 2012-04-02 2017-11-14 Modernatx, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9827332B2 (en) 2012-04-02 2017-11-28 Modernatx, Inc. Modified polynucleotides for the production of proteins
US9828416B2 (en) 2012-04-02 2017-11-28 Modernatx, Inc. Modified polynucleotides for the production of secreted proteins
US9149506B2 (en) 2012-04-02 2015-10-06 Moderna Therapeutics, Inc. Modified polynucleotides encoding septin-4
US9192651B2 (en) 2012-04-02 2015-11-24 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9675668B2 (en) 2012-04-02 2017-06-13 Moderna Therapeutics, Inc. Modified polynucleotides encoding hepatitis A virus cellular receptor 2
US9114113B2 (en) 2012-04-02 2015-08-25 Moderna Therapeutics, Inc. Modified polynucleotides encoding citeD4
US9107886B2 (en) 2012-04-02 2015-08-18 Moderna Therapeutics, Inc. Modified polynucleotides encoding basic helix-loop-helix family member E41
US9301993B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides encoding apoptosis inducing factor 1
US9216205B2 (en) 2012-04-02 2015-12-22 Moderna Therapeutics, Inc. Modified polynucleotides encoding granulysin
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9095552B2 (en) 2012-04-02 2015-08-04 Moderna Therapeutics, Inc. Modified polynucleotides encoding copper metabolism (MURR1) domain containing 1
US8999380B2 (en) 2012-04-02 2015-04-07 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9255129B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides encoding SIAH E3 ubiquitin protein ligase 1
US9050297B2 (en) 2012-04-02 2015-06-09 Moderna Therapeutics, Inc. Modified polynucleotides encoding aryl hydrocarbon receptor nuclear translocator
US9089604B2 (en) 2012-04-02 2015-07-28 Moderna Therapeutics, Inc. Modified polynucleotides for treating galactosylceramidase protein deficiency
US9587003B2 (en) 2012-04-02 2017-03-07 Modernatx, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9061059B2 (en) 2012-04-02 2015-06-23 Moderna Therapeutics, Inc. Modified polynucleotides for treating protein deficiency
US9233141B2 (en) 2012-04-02 2016-01-12 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with blood and lymphatic disorders
US9220792B2 (en) 2012-04-02 2015-12-29 Moderna Therapeutics, Inc. Modified polynucleotides encoding aquaporin-5
US9782462B2 (en) 2012-04-02 2017-10-10 Modernatx, Inc. Modified polynucleotides for the production of proteins associated with human disease
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9220755B2 (en) 2012-04-02 2015-12-29 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with blood and lymphatic disorders
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
US10434158B2 (en) 2013-02-22 2019-10-08 Curevac Ag Combination of vaccination and inhibition of the PD-1 pathway
US11458195B2 (en) 2013-02-22 2022-10-04 Curevac Ag Combination of vaccination and inhibition of the PD-1 pathway
US9974845B2 (en) 2013-02-22 2018-05-22 Curevac Ag Combination of vaccination and inhibition of the PD-1 pathway
US12447209B2 (en) 2013-02-22 2025-10-21 Cure Vac SE Combination of vaccination and inhibition of the PD-1 pathway
US10117920B2 (en) 2013-02-22 2018-11-06 Curevac Ag Combination of vaccination and inhibition of the PD-1 pathway
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2014186334A1 (en) 2013-05-15 2014-11-20 Robert Kruse Intracellular translation of circular rna
US12139513B2 (en) 2013-08-21 2024-11-12 CureVac SE Respiratory syncytial virus (RSV) vaccine
US11739125B2 (en) 2013-08-21 2023-08-29 Cure Vac SE Respiratory syncytial virus (RSV) vaccine
US11965000B2 (en) 2013-08-21 2024-04-23 CureVac SE Respiratory syncytial virus (RSV) vaccine
US12337031B2 (en) 2013-08-21 2025-06-24 CureVac SE Combination vaccine
US12083190B2 (en) 2013-08-21 2024-09-10 CureVac SE Rabies vaccine
US12240873B2 (en) 2013-08-21 2025-03-04 CureVac SE Respiratory syncytial virus (RSV) vaccine
US10815291B2 (en) 2013-09-30 2020-10-27 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
US10323076B2 (en) 2013-10-03 2019-06-18 Modernatx, Inc. Polynucleotides encoding low density lipoprotein receptor
US12533422B2 (en) 2013-11-01 2026-01-27 CureVac SE Modified RNA with decreased immunostimulatory properties
US10047375B2 (en) 2013-12-30 2018-08-14 Curevac Ag Artificial nucleic acid molecules
US11697816B2 (en) 2013-12-30 2023-07-11 CureVac SE Artificial nucleic acid molecules
US12178863B2 (en) 2014-03-12 2024-12-31 CureVac SE Combination of vaccination and OX40 agonists
US10307472B2 (en) 2014-03-12 2019-06-04 Curevac Ag Combination of vaccination and OX40 agonists
US11110157B2 (en) 2014-03-12 2021-09-07 Curevac Ag Combination of vaccination and OX40 agonists
US10022435B2 (en) 2014-04-23 2018-07-17 Modernatx, Inc. Nucleic acid vaccines
US10709779B2 (en) 2014-04-23 2020-07-14 Modernatx, Inc. Nucleic acid vaccines
US12274743B2 (en) 2014-04-23 2025-04-15 Modernatx, Inc. Nucleic acid vaccines
US12329812B2 (en) 2014-04-23 2025-06-17 Modernatx, Inc. Nucleic acid vaccines
US9872900B2 (en) 2014-04-23 2018-01-23 Modernatx, Inc. Nucleic acid vaccines
US11761009B2 (en) 2014-12-12 2023-09-19 CureVac SE Artificial nucleic acid molecules for improved protein expression
US12442005B2 (en) 2014-12-12 2025-10-14 CureVac SE Artificial nucleic acid molecules for improved protein expression
US11254951B2 (en) 2014-12-30 2022-02-22 Curevac Ag Artificial nucleic acid molecules
US10017826B2 (en) 2015-05-08 2018-07-10 Curevac Ag Method for producing RNA
US10711315B2 (en) 2015-05-08 2020-07-14 Curevac Real Estate Gmbh Method for producing RNA
US11268157B2 (en) 2015-05-08 2022-03-08 Curevac Real Estate Gmbh Method for producing RNA
US11661634B2 (en) 2015-05-08 2023-05-30 CureVac Manufacturing GmbH Method for producing RNA
US11834651B2 (en) 2015-05-29 2023-12-05 CureVac Manufacturing GmbH Method for producing and purifying RNA, comprising at least one step of tangential flow filtration
US11667910B2 (en) 2015-05-29 2023-06-06 CureVac Manufacturing GmbH Method for producing and purifying RNA, comprising at least one step of tangential flow filtration
US12221605B2 (en) 2015-05-29 2025-02-11 CureVac Manufacturing GmbH Method for producing and purifying RNA, comprising at least one step of tangential flow filtration
US11760992B2 (en) 2015-05-29 2023-09-19 CureVac Manufacturing GmbH Method for producing and purifying RNA, comprising at least one step of tangential flow filtration
US11786590B2 (en) 2015-11-09 2023-10-17 CureVac SE Rotavirus vaccines
US12318444B2 (en) 2015-11-09 2025-06-03 Cure Vac SE Rotavirus vaccines
WO2017182524A1 (en) 2016-04-22 2017-10-26 Biontech Rna Pharmaceuticals Gmbh Methods for providing single-stranded rna
EP4008782A1 (de) 2016-04-22 2022-06-08 BioNTech SE Verfahren zur bereitstellung von einzelsträngiger rna
US12168050B2 (en) 2016-05-04 2024-12-17 CureVac SE Compositions comprising a norovirus nucleic acid and methods of use thereof
US12527856B2 (en) 2016-05-04 2026-01-20 CureVac SE Artificial RNA molecules encoding a norovirus antigen and uses thereof
US12227549B2 (en) 2016-05-04 2025-02-18 CureVac SE RNA encoding a therapeutic protein
US12514918B2 (en) 2016-05-04 2026-01-06 CureVac SE Nucleic acid molecules and uses thereof
US12233084B2 (en) 2016-09-14 2025-02-25 Modernatx, Inc. High purity RNA compositions and methods for preparation thereof
US12246029B2 (en) 2016-09-14 2025-03-11 Modernatx, Inc. High purity RNA compositions and methods for preparation thereof
US11202793B2 (en) 2016-09-14 2021-12-21 Modernatx, Inc. High purity RNA compositions and methods for preparation thereof
US10653712B2 (en) 2016-09-14 2020-05-19 Modernatx, Inc. High purity RNA compositions and methods for preparation thereof
EP4035659A1 (de) 2016-11-29 2022-08-03 PureTech LYT, Inc. Exosome zur ausgabe von therapeutischen wirkstoffen
US12161711B2 (en) 2016-12-23 2024-12-10 CureVac SE Lassa virus vaccine
US11865084B2 (en) 2016-12-23 2024-01-09 CureVac SE MERS coronavirus vaccine
WO2018236617A1 (en) 2017-06-21 2018-12-27 New England Biolabs, Inc. Use of thermostable rna polymerases to produce rnas having reduced immunogenicity
US11376338B2 (en) 2017-06-21 2022-07-05 New England Biolabs, Inc. Use of thermostable RNA polymerases to produce RNAs having reduced immunogenicity
US10034951B1 (en) 2017-06-21 2018-07-31 New England Biolabs, Inc. Use of thermostable RNA polymerases to produce RNAs having reduced immunogenicity
EP4124340A1 (de) 2017-06-21 2023-02-01 New England Biolabs, Inc. Verwendung von thermostabilen rna-polymerasen zur herstellung von rnas mit reduzierter immunogenität
US20210163919A1 (en) * 2017-08-18 2021-06-03 Modernatx, Inc. Methods for hplc analysis
US11866696B2 (en) 2017-08-18 2024-01-09 Modernatx, Inc. Analytical HPLC methods
WO2019036685A1 (en) * 2017-08-18 2019-02-21 Modernatx, Inc. METHODS FOR HPLC ANALYSIS
WO2019036683A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. ANALYTICAL METHODS BY HPLC
US11912982B2 (en) * 2017-08-18 2024-02-27 Modernatx, Inc. Methods for HPLC analysis
US12385088B2 (en) 2017-12-21 2025-08-12 CureVac SE Linear double stranded DNA coupled to a single support or a tag and methods for producing said linear double stranded DNA
WO2020072914A1 (en) 2018-10-04 2020-04-09 New England Biolabs, Inc. Methods and compositions for increasing capping efficiency of transcribed rna
US11072808B2 (en) 2018-10-04 2021-07-27 New England Biolabs, Inc. Methods and compositions for increasing capping efficiency of transcribed RNA
US12528855B2 (en) 2018-12-14 2026-01-20 CureVac SE KRAS variant mRNA molecules
US12460259B2 (en) 2019-03-11 2025-11-04 Modernatx, Inc. Fed-batch in vitro transcription process
WO2021042135A2 (en) 2019-08-28 2021-03-04 Contamination Source Identification Llc Rapid isolation and collection of microbial rna from a biological specimen
WO2021195212A1 (en) * 2020-03-25 2021-09-30 Waters Technologies Corporation Devices and methods for the sensitive detection and quantitation of biomolecules
US12077560B2 (en) 2020-03-25 2024-09-03 Waters Technologies Corporation Devices and methods for the sensitive detection and quantitation of biomolecules
US12329811B2 (en) 2021-01-11 2025-06-17 Modernatx, Inc. Seasonal RNA influenza virus vaccines
WO2022162027A2 (en) 2021-01-27 2022-08-04 Curevac Ag Method of reducing the immunostimulatory properties of in vitro transcribed rna
US12168788B2 (en) 2021-01-27 2024-12-17 New England Biolabs, Inc. FCE mRNA capping enzyme compositions, methods and kits
US11098295B1 (en) 2021-01-27 2021-08-24 New England Biolabs, Inc. FCE mRNA capping enzyme compositions, methods and kits
US11725196B2 (en) 2021-01-27 2023-08-15 New England Biolabs, Inc. FCE mRNA capping enzyme compositions, methods and kits
WO2022164428A1 (en) 2021-01-27 2022-08-04 New England Biolabs, Inc. Faustovirus capping enzyme, mrna capping enzyme compositions, methods and kits
US11028379B1 (en) 2021-01-27 2021-06-08 New England Biolabs, Inc. FCE mRNA capping enzyme compositions, methods and kits
WO2022256597A1 (en) 2021-06-04 2022-12-08 Translate Bio, Inc. Assay for quantitative assessment of mrna capping efficiency
WO2023014649A1 (en) 2021-08-02 2023-02-09 Modernatx, Inc. Extraction-less reverse phase (rp) chromatography of mrna encapsulated in lipid nanoparticles for mrna purity assessment
US12529047B1 (en) 2021-12-21 2026-01-20 Modernatx, Inc. mRNA quantification methods
WO2023196950A1 (en) 2022-04-07 2023-10-12 New England Biolabs, Inc. Methods of higher fidelity rna synthesis
WO2024030369A1 (en) 2022-08-01 2024-02-08 Modernatx, Inc. Extraction-less reverse phase (rp) chromatography for mrna purity assessment
WO2025019023A1 (en) 2023-07-20 2025-01-23 New England Biolabs, Inc. Polynucleotide error recognition methods and compositions
WO2025059500A1 (en) 2023-09-14 2025-03-20 New England Biolabs, Inc. Rna polymerases
WO2025072696A1 (en) 2023-09-29 2025-04-03 New England Biolabs, Inc. Compositions, methods, and cells for making 2-aminoadenine (dz) dna
WO2025137453A1 (en) 2023-12-20 2025-06-26 New England Biolabs, Inc. Compositions, methods, kits, and instruments for analyzing rna structure
US12492420B2 (en) 2024-03-29 2025-12-09 New England Biolabs, Inc. Compositions, kits, and methods for in vitro transcription
WO2025208142A2 (en) 2024-03-29 2025-10-02 New England Biolabs, Inc. Compositions, kits, and methods for in vitro transcription
WO2025213179A1 (en) 2024-04-05 2025-10-09 New England Biolabs, Inc. Compositions and methods for characterizing rna
WO2025227034A1 (en) 2024-04-26 2025-10-30 New England Biolabs, Inc. Salt active nuclease compositions and methods
WO2026010863A2 (en) 2024-07-01 2026-01-08 New England Biolabs, Inc. Programmable cleavage of rna

Also Published As

Publication number Publication date
KR101183173B1 (ko) 2012-09-14
AU2007338360B2 (en) 2011-06-02
JP2010512767A (ja) 2010-04-30
PL2092064T3 (pl) 2011-03-31
EP2092064A1 (de) 2009-08-26
ES2352306T3 (es) 2011-02-17
CN101563457B (zh) 2014-03-12
ATE481482T1 (de) 2010-10-15
DE102006061015A1 (de) 2008-06-26
DE602007009295D1 (de) 2010-10-28
CA2670727A1 (en) 2008-07-03
US20100048883A1 (en) 2010-02-25
DK2092064T3 (da) 2010-12-13
WO2008077592A1 (en) 2008-07-03
EP2092064B1 (de) 2010-09-15
CA2670727C (en) 2012-10-09
JP5307724B2 (ja) 2013-10-02
KR20090098968A (ko) 2009-09-18
AU2007338360A1 (en) 2008-07-03
CN101563457A (zh) 2009-10-21

Similar Documents

Publication Publication Date Title
US8383340B2 (en) Method for purifying RNA on a preparative scale by means of HPLC
Tian et al. Evaluation of silica resins for direct and efficient extraction of DNA from complex biological matrices in a miniaturized format
Eon-Duval et al. Purification of pharmaceutical-grade plasmid DNA by anion-exchange chromatography in an RNase-free process
Urthaler et al. Improved downstream process for the production of plasmid DNA for gene therapy.
JP3714940B2 (ja) Ｒｎａ抽出方法、および生体材料の分析方法
JP3379758B2 (ja) イソプロパノール含有水溶液を用いる核酸のトランスフェクション効率の増強
ES2654539T3 (es) Procedimiento para el aislamiento de ADN a partir de muestras biológicas
Hanora et al. Direct capture of plasmid DNA from non-clarified bacterial lysate using polycation-grafted monoliths
Poeckh et al. Adsorption and elution characteristics of nucleic acids on silica surfaces and their use in designing a miniaturized purification unit
AU2007321877A1 (en) Pharmaceutical manufacturing methods
EP1337627B1 (de) Methode zur reinigung von adenoviren
US20240327847A1 (en) Compositions and methods for rna affinity
WO2005111059A2 (en) Process for the reduction of endotoxins
CN107629129B (zh) 生产和纯化多肽的方法
Smrekar et al. Single step plasmid DNA purification using methacrylate monolith bearing combination of ion-exchange and hydrophobic groups
Spector et al. Polyadenylic acid on poliovirus RNA: IV. Poly (U) in replicative intermediate and double-stranded RNA
EP0979868B1 (de) Elektrophoretischer Trennung von Nukleinsäuren aus biologischen Proben bei niedrigem pH-Wert
ES2373976T3 (es) Procedimiento y kit de análisis para la separación, purificación y recuperación de ácidos nucleicos de cadena larga y de cadena corta.
JP4073429B2 (ja) Ｒｎａ抽出用試薬
JP4073447B2 (ja) Ｒｎａ抽出方法、ｒｎａ抽出用試薬、および生体材料の分析方法
CN115960244B (zh) 重组α-1,3-半乳糖基转移酶及其制备方法和应用
CN115803335A (zh) 用于增强断裂型内含肽的稳定性和溶解度的方法和组合物
JP2006271292A (ja) メッセンジャーｒｎａの分離方法
Matos Nucleic Acids: Innovative Methods for Recovery, Clarification and Purification

Legal Events

Date Code Title Description
AS Assignment

Owner name: CUREVAC GMBH,GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KETTERER, THOMAS;VON DER MULBE, FLORIAN;REIDEL, LADISLAUS;AND OTHERS;SIGNING DATES FROM 20090701 TO 20090721;REEL/FRAME:023388/0888

Owner name: CUREVAC GMBH, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KETTERER, THOMAS;VON DER MULBE, FLORIAN;REIDEL, LADISLAUS;AND OTHERS;SIGNING DATES FROM 20090701 TO 20090721;REEL/FRAME:023388/0888

STCF Information on status: patent grant

Free format text: PATENTED CASE

AS Assignment

Owner name: CUREVAC AG, GERMANY

Free format text: CHANGE OF NAME;ASSIGNOR:CUREVAC GMBH;REEL/FRAME:037115/0430

Effective date: 20150917

FEPP Fee payment procedure

Free format text: PAT HOLDER NO LONGER CLAIMS SMALL ENTITY STATUS, ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: STOL); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 4

SULP Surcharge for late payment
IPR Aia trial proceeding filed before the patent and appeal board: inter partes review

Free format text: TRIAL NO: IPR2017-02194

Opponent name: MODERNATX, INC.

Effective date: 20170929

RF Reissue application filed

Effective date: 20190617

AS Assignment

Owner name: CUREVAC REAL ESTATE GMBH, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CUREVAC AG;REEL/FRAME:051487/0680

Effective date: 20191119

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 8

AS Assignment

Owner name: CUREVAC MANUFACTURING GMBH, GERMANY

Free format text: CHANGE OF NAME;ASSIGNOR:CUREVAC REAL ESTATE GMBH;REEL/FRAME:062800/0087

Effective date: 20220802

FEPP Fee payment procedure

Free format text: 11.5 YR SURCHARGE- LATE PMT W/IN 6 MO, LARGE ENTITY (ORIGINAL EVENT CODE: M1556); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1553); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 12